Core Insights - Amicus Therapeutics, Inc. has experienced a significant stock price increase of 30.21%, closing at $14.18, following the announcement of its merger with BioMarin Pharmaceutical for nearly $5 billion [1][2] - The acquisition deal is an all-cash transaction priced at $14.50 per share, representing a 33% premium over Amicus's previous closing price of $10.89 [3] - The merger has received approval from both companies' boards but is still pending regulatory and shareholder approvals [3] Company Performance - Amicus Therapeutics reached a new 52-week high during trading, peaking at $14.36 before closing at $14.18 [2] - The company has developed two transformative medicines for rare diseases, impacting over 3,400 patients globally [4] Strategic Outlook - The CEO of Amicus Therapeutics expressed confidence that the merger will enhance the reach of its medicines, benefiting more patients and accelerating progress in the rare disease community [5]

Core Viewpoint - Needham downgraded Amicus Therapeutics from Buy to Hold amid significant developments in the biotech sector, particularly following BioMarin Pharmaceutical's acquisition of Amicus valued at $4.8 billion [1][6]. Company Summary - Amicus Therapeutics is a biotechnology company focused on developing therapies for rare diseases [1]. - The company's stock price is currently at $14.21, reflecting a notable increase of 30.43% or $3.31, driven by investor interest related to the acquisition news [3][6]. - Amicus has a market capitalization of approximately $4.38 billion, with a trading volume of about 132.8 million shares [4]. Industry Summary - BioMarin Pharmaceutical's acquisition of Amicus is part of a broader trend of consolidation in the biotech industry, aimed at expanding capabilities and product offerings [2][5]. - The acquisition is expected to enhance BioMarin's portfolio by adding two rare disease drugs from Amicus, strengthening its market position and driving future growth [2][5].

Core Insights - The article discusses the latest trends and developments in the investment banking sector, highlighting key financial metrics and market movements. Group 1: Industry Trends - Investment banking is experiencing a shift towards digital transformation, with firms increasingly adopting technology to enhance efficiency and client engagement [1] - The competitive landscape is intensifying, with new entrants leveraging innovative business models to capture market share [1] Group 2: Company Performance - Major investment banks reported a 15% increase in revenue year-over-year, driven by strong performance in advisory services and capital markets [1] - Cost management strategies have led to a 10% reduction in operational expenses across the sector, improving overall profitability [1]

Market Overview - U.S. stocks traded higher, with the Nasdaq Composite gaining over 1% on Friday, while the Dow rose 0.55% to 48,216.43, and the S&P 500 increased by 0.83% to 6,830.85 [1] - Information technology shares rose by 1.6%, while consumer staples stocks fell by 0.4% [1] Company Performance - Nike Inc. shares fell around 10% despite reporting second-quarter revenue of $12.43 billion, exceeding analyst estimates of $12.22 billion, and earnings of 53 cents per share, surpassing estimates of 38 cents per share. The decline in gross margins for the second consecutive quarter contributed to the stock's drop [2] Commodity Market - Oil prices increased by 0.9% to $56.66, gold rose by 0.4% to $4,381.60, silver surged 3.4% to $67.415, and copper gained 1.1% to $5.4955 [5] European Market - European shares were higher, with the eurozone's STOXX 600 gaining 0.37%, Spain's IBEX 35 Index rising 0.22%, London's FTSE 100 up by 0.61%, Germany's DAX 40 increasing by 0.37%, and France's CAC 40 gaining 0.01% [6] Asian Market - Asian markets closed higher, with Japan's Nikkei 225 gaining 1.03%, Hong Kong's Hang Seng up by 0.75%, China's Shanghai Composite rising 0.36%, and India's BSE Sensex increasing by 0.53% [7] Notable Stock Movements - Autozi Internet Technology shares surged 54% to $2.34 after announcing a $90 million initial equity investment [9] - Amicus Therapeutics shares rose 31% to $14.20 following the announcement of its acquisition by BioMarin for a total equity value of about $4.8 billion, with BioMarin shares up 19% to $61.88 [9] - Lamb Weston Holdings shares dropped 25% to $44.70 after second-quarter results, while BlackBerry shares fell 10% to $3.90 following third-quarter results [9] - Mangoceuticals Inc. shares declined 45% to $0.72 after announcing a $100 million Solana-focused digital asset treasury strategy [9]

U.S. stocks were higher, with the Dow Jones index gaining more than 250 points on Friday.Shares of Carnival PLC (NYSE:CUK) rose sharply during Thursday's session after the company announced better-than-expected fourth-quarter adjusted EPS results and issuedFY26 adjusted EPS guidance above estimates.Carnival shares jumped 16.3% to $30.61 on Friday.Here are some other big stocks recording gains in today’s session.NovaBay Pharmaceuticals Inc (NYSE:NBY) shares jumped 45.1% to $4.28.Intuitive Machines Inc (NASDA ...

渤健制药（BMRN）于周五宣布，将以约 48 亿美元的价格收购阿米库斯治疗公司（FOLD），此举旨 在扩大其在罕见代谢性疾病领域的业务版图。 渤健将以每股 14.50 美元的价格收购阿米库斯治疗公司股份，较该公司最新收盘价溢价 33.1%。受此消 息影响，阿米库斯治疗公司股价暴涨 30%，渤健股价在盘前交易中也上涨了近 5%。 通过这笔交易，渤健的产品组合将得到进一步充实，获得阿米库斯治疗公司已获批的多款遗传病治疗药 物。其中包括治疗法布里病的口服药加拉福，法布里病是由基因缺陷引发的疾病，会导致脂肪类物质在 细胞内堆积。 责任编辑：郭明煜 渤健制药（BMRN）于周五宣布，将以约 48 亿美元的价格收购阿米库斯治疗公司（FOLD），此举旨 在扩大其在罕见代谢性疾病领域的业务版图。 渤健将以每股 14.50 美元的价格收购阿米库斯治疗公司股份，较该公司最新收盘价溢价 33.1%。受此消 息影响，阿米库斯治疗公司股价暴涨 30%，渤健股价在盘前交易中也上涨了近 5%。 通过这笔交易，渤健的产品组合将得到进一步充实，获得阿米库斯治疗公司已获批的多款遗传病治疗药 物。其中包括治疗法布里病的口服药加拉福，法布里病是由基因 ...

MILWAUKEE, Dec. 19, 2025 /PRNewswire/ -- The Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.  There is no cost or obligation to you. In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at a ...

Core Viewpoint - The law firm Halper Sadeh LLC is investigating the fairness of the sale of Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc. at a price of $14.50 per share for Amicus shareholders [1]. Company Summary - Amicus Therapeutics, Inc. is being sold to BioMarin Pharmaceutical Inc. for $14.50 per share [1]. - The investigation by Halper Sadeh LLC focuses on whether this sale price is fair to Amicus shareholders [1]. Legal Rights and Options - Halper Sadeh encourages Amicus shareholders to learn more about their legal rights and options regarding the sale [1]. - Shareholders can contact Daniel Sadeh or Zachary Halper for further information [1].

Group 1 - BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics for approximately $4.8 billion in cash [1]

Core Viewpoint - BioMarin Pharmaceutical is set to acquire Amicus Therapeutics in an all-cash transaction valued at approximately $4.8 billion [1] Company Summary - The acquisition will enhance BioMarin's portfolio and expand its capabilities in the biotechnology sector [1] - The deal signifies BioMarin's strategic move to strengthen its position in the market through consolidation [1] Financial Summary - The total value of the acquisition is around $4.8 billion, indicating a significant investment by BioMarin [1]